MedPage Today on MSN3d
Can Flu Shot Nudges Lead to Fewer COVID Vaccinations?Receiving an electronic reminder about influenza vaccination appeared to decrease COVID vaccination rates. Further study of ...
The asthma medication reduces congestion in patients with severe, uncontrolled chronic rhinosinusitis with nasal polyps in a ...
AstraZeneca is hopping aboard the pickleball craze as its serves up a new marketing push for its asthma med Fasenra. | ...
In 2025, Cellectis will continue to focus its efforts and expenses on advancing its core clinical trials BALLI-01 and NATHALI ...
Investor's Business Daily on MSN20h
AstraZeneca Stock Nears Buy Point After Long Run In Declining MarketAstraZeneca is Thursday's pick for IBD 50 Growth Stocks To Watch as the biopharmaceutical name is holding up relatively well ...
STORY: Stubborn inflation and President Donald Trump’s trade policies have rekindled fears of stagflation, a troubling ...
Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns.
AstraZeneca is preparing to talk to the FDA about a potential new use of its immunotherapy Imfinzi after a pivotal study in ...
Pharmaceutical Technology on MSN3d
AstraZeneca and Ionis win EU approval for ATTR polyneuropathyAstraZeneca and Ionis Pharmaceuticals’ polyneuropathy drug has won approval in the European Union (EU), where it will be ...
A cohort study of over 40,000 patients suggests that levels should be monitored for at least three months — longer than commonly practiced ...
The AstraZeneca PLC ADR AZN rose 1.79% to $75.57 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ Composite Index COMP rising 1.22% to ...
Imfinzi is one of AstraZeneca’s key growth drivers for 2025, with potential approvals in stomach and bladder cancers. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback